Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Esthesioneuroblastoma, Olfactory 1Adenocarcinoma, Follicular 1

Interventions

vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1sargramostim 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1entinostat 1aldesleukin 1Surgical Procedures, Operative 1Semaxinib 1Ritonavir 1Radiotherapy 1Photochemotherapy 1Paclitaxel 1Indinavir 1Gefitinib 1Fentanyl 1Docetaxel 1Congresses as Topic 12-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × Congresses as Topic × Endocrine × Clear all
NCT00470496 2022-07-25

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1 Completed
15 enrolled
CNSEndocrineHead & Neck

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡